Microba Life SciencesASX:MAP +2.56% Days Payable is 165.93 as of Dec. 2025, which is 0% above its 10-year median of 165.64. The stock has 6 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 79.47% on this metric.
The historical rank and industry rank for Microba Life Sciences's Days Payable or its related term are showing as below:
ASX:MAP'
s Days Payable Range Over the Past 10 Years
Min: 127.74 Med: 165.64 Max: 252.58
Current: 176.52
During the past 4 years, Microba Life Sciences's highest Days Payable was 252.58. The lowest was 127.74. And the median was 165.64.
ASX:MAP's Days Payable is ranked better than 79.47% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs ASX:MAP: 176.52
Microba Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MAP vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Microba Life Sciences's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) has a Days Payable of 165.93 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Microba Life Sciences and its competitors. This is near median its historical median of 165.64. Over the past decade, Microba Life Sciences' Days Payable has ranged from 127.74 to 252.58. According to the industry distribution chart, Microba Life Sciences ranks #39 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 20.5%.
Is Microba Life Sciences' Days Payable too high?
Microba Life Sciences' current Days Payable of 165.93 is near median its 10-year median of 165.64. Over the past 10 years, this metric has ranged from a low of 127.74 to a high of 252.58. The Medical Diagnostics & Research industry median Days Payable is 67.28. Microba Life Sciences' value of 165.93 is 146.6% above this industry median. Based on the distribution chart, Microba Life Sciences ranks #39 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Microba Life Sciences' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #39 out of 190 companies for Days Payable. This places Microba Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Microba Life Sciences' value of 165.93 is 146.6% above this benchmark. Historically, Microba Life Sciences' own Days Payable has ranged from 127.74 to 252.58 over the past decade. While the company's 10-year median is 165.64 vs. the industry median of 67.28, Microba Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current Days Payable of 165.93 is 146.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current Days Payable is 165.93, which is near median its own 10-year median of 165.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84% below its estimated fair value. The current Days Payable is 165.93, which is near median its 10-year median of 165.64 and 146.6% above the Medical Diagnostics & Research industry median of 67.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Days Payable is 165.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 